Claims:

1. Use of an antibody having the ability of binding to CLDN18.2 for the preparation of a medicament for treating or preventing a cancer disease in combination with an agent stabilizing or increasing expression of CLDN18.2, wherein
(a) the antibody binds to CLDN18.2 and mediates killing of cells expressing CLDN18.2 by ADCC and/or CDC, and
(b) the agent stabilizing or increasing expression of CLDN18.2 is selected from the group consisting of (i) oxaliplatin and 5-fluorouracil, (ii) epirubicin, oxaliplatin and 5-fluorouracil; (iii) 5-fluorouracil, folinic acid and oxaliplatin, (iv) Irinotecan, (v) Docetaxel and (vi) Cisplatin, and prodrugs thereof.

2. The use of claim 1, wherein the antibody comprises an antibody heavy chain comprising the amino acid sequence represented by SEQ ID NO: 32 and an antibody light chain comprising the amino acid sequence represented by SEQ ID NO: 39.

3. The use of claim 1 or 2, wherein the antibody heavy chain comprises the amino acid sequence represented by SEQ ID NO: 17 and the antibody light chain comprises the amino acid sequence represented by SEQ ID NO: 24.

4. The use of any one of claims 1 to 3, further comprising an agent stimulating γδ T cells, wherein the agent is a bisphosphonate.

5. The use of claim 4, wherein said bisphosphonate is a nitrogen containing bisphosphonate or is selected from the group consisting of zoledronic acid, clodronic acid, ibandronic acid, pamidronic acid, risedronic acid, minodronic acid, olpadronic acid, alendronic acid, incadronic acid and salts thereof.

6. The use of claim 4 or 5, wherein the γδ T cells are Vγ9Vδ2 T cells.

7. The use of any one of claims 1 to 6, wherein the treatment comprises the antibody to be administered at a dose of up to 1000 mg/m^2.

8. The use of any one of claims 1 to 7, wherein the treatment comprises the antibody to be administered at a dose of 300 to 600 mg/m^2.

9. The use of any one of claims 1 to 8, wherein the cancer is CLDN18.2 positive.

10. The use of any one of claims 1 to 9, wherein the cancer is an adenocarcinoma.

11. The use of claim 10, wherein the adenocarcinoma is an advanced adenocarcinoma.

12. The use of any one of claims 1 to 11, wherein the cancer is selected from the group consisting of cancer of the stomach, cancer of the esophagus, cancer of the eso-gastric junction and gastroesophageal cancer.

13. The use of claim 12, wherein the cancer of the esophagus is a cancer of the lower esophagus.

14. The use of any one of claims 1 to 13, wherein the patient is a HER2/neu negative patient or a patient with HER2/neu positive status but not eligible to trastuzumab therapy.

15. The use of any one of claims 1 to 14, wherein CLDN18.2 has the amino acid sequence according to SEQ ID NO: 1.

16. A medical preparation for treating or preventing cancer, said preparation comprising an antibody and an agent, wherein
(a) the antibody binds to CLDN18.2 and mediates killing of cells expressing CLDN18.2 by ADCC and/or CDC, and
(b) the agent is an agent stabilizing or increasing expression of CLDN18.2, said agent being selected from the group consisting of (i) oxaliplatin and 5-fluorouracil, (ii) epirubicin, oxaliplatin and 5-fluorouracil; (iii) 5-fluorouracil, folinic acid and oxaliplatin, (iv) Irinotecan, (v) Docetaxel and (vi) Cisplatin and prodrugs thereof.

17. The medicinal preparation of claim 16, wherein the antibody comprises an antibody

heavy chain comprising the amino acid sequence represented by SEQ ID NO: 32 and an antibody light chain comprising the amino acid sequence represented by SEQ ID NO: 39.

18. The medical preparation of claim 16 or 17, wherein the antibody heavy chain comprises the amino acid sequence represented by SEQ ID NO: 17 and the antibody light chain comprises the amino acid sequence represented by SEQ ID NO: 24.

19. A kit for treating or preventing cancer, said kit comprising a first container including an antibody and a container including an agent stabilizing or increasing expression of CLDN18.2, wherein
(a) the antibody binds to CLDN18.2 and mediates killing of cells expressing CLDN18.2 by ADCC and/or CDC, and
(b) the agent stabilizing or increasing expression of CLDN18.2 is selected from the group consisting of (i) oxaliplatin and 5-fluorouracil, (ii) epirubicin, oxaliplatin and 5-fluorouracil; (iii) 5-fluorouracil, folinic acid and oxaliplatin, (iv) Irinotecan, (v) Docetaxel and (vi) Cisplatin and prodrugs thereof.

20. The kit of claim 19, wherein the antibody comprises an antibody heavy chain comprising the amino acid sequence represented by SEQ ID NO: 32 and an antibody light chain comprising the amino acid sequence represented by SEQ ID NO: 39.

21. The kit of claim 19 or 20, wherein the antibody heavy chain comprises the amino acid sequence represented by SEQ ID NO: 17 and the antibody light chain comprises the amino acid sequence represented by SEQ ID NO: 24.

22. The medical preparation of any one of claims 16 to 18 or the kit of any one of claims 19 to 21, further including printed instructions for use of the preparation for treatment of cancer.